Since 2013, Abbott has continued to improve the profitability of its four segments: nutritionals, devices, diagnostics, and established pharmaceuticals. Although the company has made progress over the last 10 years, it still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.
Abbott has been investing in structural heart products and recently entered the left atrial appendage closure market.
Clinical data on drug-eluting stents and alternative therapies have put a crimp in percutaneous coronary procedures, as medical therapy and coronary bypass have gained favor.
|
Metric
|
ABT
|
BSX
|
RHHBY
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.22 | 28.43 | 12.98 |
Price/Book Value | 4.80 | 4.30 | 7.33 |
Price/Sales | 4.54 | 5.86 | 3.32 |
Price/Cash Flow | 24.56 | 29.53 | 11.19 |
|
Metric
|
ABT
|
BSX
|
RHHBY
|
|---|---|---|---|
Quick Ratio | 1.23 | 0.67 | 0.72 |
Current Ratio | 1.74 | 1.42 | 1.18 |
Interest Coverage | 10.19 | 8.07 | 17.42 |
|
Metric
|
ABT
|
BSX
|
RHHBY
|
|---|---|---|---|
Return on Assets (Normalized) | 10.26% | 8.56% | 17.37% |
Return on Equity (Normalized) | 20.43% | 15.65% | 56.49% |
Return on Invested Capital (Normalized) | 14.39% | 10.89% | 27.41% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
SYK
| Stryker Corp | Xlnx | $111.8 Bil | |
MDT
| Medtronic PLC | Rljv | $104.9 Bil | |
BSX
| Boston Scientific Corp | Fmdtvss | $81.2 Bil | |
DXCM
| DexCom Inc | Ybhdf | $44.3 Bil | |
EW
| Edwards Lifesciences Corp | Bpvsrz | $40.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Jjnr | $23.8 Bil | |
PHG
| Koninklijke Philips NV ADR | Qfrmtl | $19.0 Bil | |
ALGN
| Align Technology Inc | Rdkdzyh | $16.6 Bil | |
PODD
| Insulet Corp | Bvjzgz | $13.2 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)